Research To Practice | Oncology Videos

Featuring perspectives from Dr Sara Tolaney, including the following topics: • Introduction (00:00) • Case: A premenopausal woman in her early 30s with T1c N0 ER/PR-positive, HER2-negative, gBRCA2-mutant invasive ductal carcinoma (IDC) with an Oncotype DX® Recurrence Score® (RS) of 30 receives adjuvant chemotherapy followed by leuprolide/letrozole but wishes to discontinue treatment to attempt pregnancy — Alan B Astrow, MD (10:19) • Case: A woman in her late 30s with T2 N0 ER/PR-positive, HER2-negative IDC and RS of 35 has severe menopause after adjuvant TC, TAH/BSO and letrozole — Ranju Gupta, MD (22:18) • Case: A postmenopausal woman in her early 50s with bilateral ER-positive, HER2-negative breast cancer; RS on the left is low and on the right is 30 but the tumor is 4 millimeters — Zanetta S Lamar, MD (34:19) • Case: A premenopausal woman in her early 40s with a gBRCA2 mutation and Stage IIB ER/PR-positive, HER2-low (IHC 1+) IDC treated with adjuvant tamoxifen develops extensive metastases and receives ovarian function suppression, letrozole and palbociclib — Jeremy Lorber, MD (38:57) • Case: A woman in her early 70s with multiregimen-recurrent ER/PR-positive, HER2-low (IHC 1+) metastatic breast cancer receives T-DXd — Henna Malik, MD (54:25) • Case: A woman in her mid 40s with node-positive localized triple-negative breast cancer has residual disease after neoadjuvant pembrolizumab/chemotherapy and surgery — Laila Agrawal, MD (57:05) CME information and select publications

Featuring perspectives from Dr Matthew Galsky, Jonathan Rosenberg, and Dr Arlene Siefker-Radtke, moderated by Dr Elisabeth Heath, including the following topics: • Integrating Novel Treatment Strategies into the Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Galsky o Introduction (00:00) o Case: A man in his late 70s with superficial transitional cell carcinoma of the bladder after bacillus Calmette-Guérin with positive ureteral washing — Sunil Gandhi, MD (2:38) o Cases: A man in his early 70s with high-grade papillary muscle-invasive bladder cancer with residual disease after neoadjuvant gemcitabine/cisplatin and cystectomy and a man in his early 80s with pT3N0 high-grade urothelial carcinoma after nephroureterectomy (GFR 40) — Ranju Gupta, MD and Swati Vishwanathan, MD (7:04) o Faculty presentation: Dr Galsky (13:16) • Current and Future Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg o Cases: A man in his mid 70s with metastatic urothelial carcinoma now on maintenance avelumab after gemcitabine/cisplatin and a man in his early 50s with a history of ulcerative colitis diagnosed with metastatic urothelial carcinoma, including brain involvement — Paul Markowski, MD and Gigi Chen, MD) (23:33) o Case: A woman in her early 80s with unresectable localized urothelial carcinoma; PD-L1 CPS 5, TMB low — Spencer H Bachow, MD (30:54) o Faculty presentation: Dr Rosenberg (36:21) • Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke o Case: A man in his mid 60s with metastatic bladder cancer and progressive disease on cisplatin/gemcitabine, now receiving sacituzumab govitecan — Priya Rudolph, MD, PhD (46:49) o Case: A man in his mid 60s with de novo metastatic urothelial bladder cancer now receiving pembrolizumab after gemcitabine/carboplatin (rapid progressive disease, FGFR3 mutation) — Yanjun Ma, MD (51:42) o Faculty presentation: Dr Siefker-Radtke (56:56) • Novel Investigational Agents and Strategies in the Treatment of mUBC — Dr Heath o Case: A man in his late 60s with metastatic urothelial carcinoma, PS 2 — Georges Azzi, MD (1:09:30) o Cases: A man in his mid 70s with metastatic mixed-histology (urothelial, small cell) bladder cancer who receives pembrolizumab and remains in remission 5 years later and a man in his early 50s with metastatic small cell carcinoma of the bladder who receives cisplatin, etoposide and durvalumab followed by maintenance durvalumab, now NED — Victoria Giffi, MD and Laurie Matt-Amaral, MD, MPH (1:13:48) o Faculty presentation: Dr Heath (1:19:43) CME information and select publications

Featuring perspectives from Dr Emmanuel Antonarakis, Prof Karim Fizazi, Dr Maha Hussain and Dr Matthew Smith, moderated by Dr Alan Bryce, including the following topics: • Management Approaches for Nonmetastatic Prostate Cancer — Dr Bryce o Introduction (00:00) o Case: A man in his early 70s with Gleason 8 prostate cancer after EBRT and leuprolide/enzalutamide, now receiving leuprolide/darolutamide with focal prostate uptake on PSMA PET — Priya Rudolph, MD, PhD (3:04) o Case: A man in his late 60s who underwent prostatectomy for Gleason 4 + 3 = 7 prostate cancer, now with increasing PSA levels — Nataliya Mar, MD (8:35) o Faculty presentation: Dr Bryce (15:12) • Optimizing the Care of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Hussain o Cases: A man in his early 70s with de novo mHSPC and a man in his mid 90s with de novo mHSPC — Georges Azzi, MD and Swati Vishwanathan, MD (23:29) o Case: A man in his early 70s with atrial fibrillation and rapid ventricular response who is diagnosed with de novo mHSPC (PSA 180,000 ng/mL) — Eric H Lee, MD, PhD (32:37) o Faculty presentation: Dr Hussain (37:34) • Current Therapeutic Options for Patients with Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Smith o Case: A man in his early 60s with de novo metastatic prostate cancer — Lai (Amber) Xu, MD, PhD (48:49) o Case: A man in his late 70s with mCRPC — Dr Rudolph (53:36) o Faculty presentation: Dr Smith (58:37) • Best Practice Management of mCRPC for Patients Harboring HRR Gene Alterations — Dr Antonarakis o Case: A man in his mid 70s with mCRPC with an ATM mutation who receives olaparib — Dr Vishwanathan (1:06:38) o Case: A man in his mid 70s with de novo mCRPC with a BRCA2 mutation who received multiple treatments and is now responding to olaparib but with transfusion-dependent neutropenia — Sunil Gandhi, MD (1:17:00) o Faculty presentation: Dr Antonarakis (1:21:30) • Current and Emerging Strategies for Patients with Recurrent mCRPC — Prof Fizazi o Case: A robust man in his mid 80s with mCRPC and rapid, symptomatic progressive disease through multiple treatments, now with extensive liver and bone metastases and small cell transformation — Vignesh Narayanan, MD (1:32:58) o Case: A man in his mid 70s with BRCA wild-type mHSPC who enrolls on a clinical trial of ADT/enzalutamide with or without a PD-1 inhibitor — David S Morris, MD (1:37:50) o Faculty presentation: Prof Fizazi (1:45:18) CME information and select publications

Featuring an interview with Drs Gottfried Konecny and Chirag Patel, including the following topics: • Tumor Treating Fields with Chirag B Patel, MD, PhD o Introduction (0:00) o Mechanism of action of tumor treating fields (5:53) o Tumor treating fields for glioblastoma multiforme (25:08) o Tumor treating fields for other tumor types (28:50) o Case presentations (34:10) • Updates on PARP Inhibitors in 2023 with Gottfried E Konecny, MD o PARP inhibitors as up-front maintenance therapy for ovarian cancer (37:15) o PARP inhibitors for recurrent ovarian cancer (44:34) CME information and select publications

Featuring perspectives from Dr Richard Finn, Dr Lipika Goyal and Prof Arndt Vogel, moderated by Dr Katie Kelley, including the following topics: • First-Line Treatment for Advanced Hepatocellular Carcinoma (HCC) — Dr Finn o Introduction (0:00) o Case: A man in his early 70s with newly diagnosed metastatic HCC receives atezolizumab/bevacizumab — Warren S Brenner, MD (2:27)) o Case: A woman in her late 50s with a history of hepatitis C and chronic kidney disease on dialysis with localized HCC after surgical resection; patient developed metastatic disease 10 months later — Liudmila N Schafer, MD (6:48) o Faculty presentation: Dr Finn (11:47) • Selection and Sequencing of Therapies for Relapsed/Refractory HCC — Dr Kelley o Case: A man in his mid 60s with metastatic HCC and a medical history of hepatitis C develops interstitial lung disease on atezolizumab/bevacizumab — Priya Rudolph, MD (21:48) o Cases: A man in his late 60s with post-transplant recurrence develops metastatic HCC and receives lenvatinib followed by cabozantinib followed by regorafenib and a man in his late 70s with metastatic HCC after treatment with atezolizumab/bevacizumab, lenvatinib and currently cabozantinib — Lionel A Kankeu Fonkoua, MD and Susmitha Apuri, MD (26:58) o Faculty presentation: Dr Kelley (35:56) • Current and Future Role of Immunotherapy in the Treatment of Advanced Biliary Tract Cancers (BTCs) — Prof Vogel o Case: A woman in her mid 70s with metastatic cholangiocarcinoma who received first-line gemcitabine/cisplatin with durvalumab — Dr Brenner (45:40) o Case: A man in his early 70s with localized cholangiocarcinoma deemed potentially resectable with tumor response — Jeremy Lorber, MD (50:23) o Faculty presentation: Dr Vogel (55:10) • Integration of Targeted Therapy into the Management of Advanced BTCs — Dr Goyal o Cases: A woman in her late 70s with intrahepatic cholangiocarcinoma considered unresectable — an FGFR2-KIAA1598 fusion was detected on NGS and a man in his early 60s with metastatic cholangiocarcinoma with severe muscle pain on pemigatinib — Dr Fonkoua and Joseph Martins, MD (1:06:18) o Cases: A man in his early 50s with recurrent metastatic cholangiocarcinoma with a BRAF V600E mutation treated with dabrafenib/trametinib and a woman in her mid 60s with cholangiocarcinoma with an IDH1 mutation receives ivosidenib — Farshid Dayyani, MD, PhD and Niyati A Nathwani, MD (1:12:26) o Faculty presentation: Dr Goyal (1:19:08) CME information and select publications

Featuring perspectives from Prof Laurence Albiges, Dr Toni Choueiri and Prof Thomas Powles, moderated by Dr Brian Rini, including the following topics: • Available Data with and Ongoing Investigation of Immune Checkpoint Inhibitors for Nonmetastatic Renal Cell Carcinoma (RCC) — Prof Powles o Introduction (0:00) o Case: A woman in her early 60s after left nephrectomy (T3aN0M0 clear cell carcinoma) — Swati Vishwanathan, MD (1:39) o Cases: A man in his early 50s develops renal dysfunction after 2 cycles of adjuvant pembrolizumab for RCC and a man in his late 60s with Stage III clear cell RCC (ccRCC) discontinues adjuvant pembrolizumab due to severe musculoskeletal pain and joint swelling — Justin Peter Favaro, MD, PhD and Priya Rudolph, MD, PhD (6:05) o Faculty presentation: Prof Powles (11:03) • Evidence-Based Selection of First-Line Therapy for Metastatic RCC — Dr Choueiri o Case: A man in his early 70s with metastatic RCC enrolls on the PDIGREE trial and receives nivolumab/ipilimumab without response followed by cabozantinib — Helen H Moon, MD (21:32) o Cases: A man in his early 70s receives ipilimumab/nivolumab for widely metastatic RCC and develops autoimmune hepatitis and a man in his early 60s with metastatic ccRCC receives ipilimumab/nivolumab followed by nivolumab with response but develops hypothyroidism and hypoadrenalism — Victoria Giffi, MD and Philip L Brooks, MD (25:33) o Faculty presentation: Dr Choueiri (36:38) • Treatment Options for Relapsed/Refractory RCC — Dr Rini o Case: A woman in her early 60s with metastatic ccRCC receives lenvatinib/pembrolizumab but develops difficult-to-manage hypertension — Eric H Lee, MD, PhD (46:04) o Case: A woman in her mid 60s with metastatic ccRCC and somatic VHL gene mutation receives ipilimumab/nivolumab and develops a solitary brain metastasis — Sunil Gandhi, MD (52:36) o Faculty presentation: Dr Rini (57:54) • Management of RCC Among Special Patient Populations — Prof Albiges o Case: A man in his late 60s with Waldenström macroglobulinemia and metastatic papillary RCC receives first-line ipilimumab/nivolumab followed by nivolumab but develops disease progression, including brain metastases — Nikesh Jasani, MD (1:07:58) o Case: A woman in her early 70s with a history of psoriatic arthritis develops metastatic ccRCC, receives pembrolizumab/axitinib and develops elevated liver function tests — Georges Azzi, MD (1:12:38) o Faculty presentation: Prof Albiges (1:18:45) CME information and select publications

Featuring perspectives from Dr Christopher Lieu, including the following topics: • Early-Onset Colorectal Cancer o Introduction (00:00) • Localized Disease o Case: A woman in her mid 30s with left-sided T3N0 Grade II obstructing adenocarcinoma of the colon — William R Mitchell, MD (16:31) o Case: A woman in her early 50s with Stage II mismatch repair-proficient sigmoid colon cancer with focal intramural lymphovascular invasion after 6 cycles of adjuvant capecitabine — Priya Rudolph, MD, PhD (19:51) • Metastatic Disease o Case: A woman in her mid 80s with pan-RAS wild-type (WT) metastatic rectal cancer with poor tolerance to chemotherapy, now receiving regorafenib with slowly progressive disease — Eric H Lee, MD, PhD (32:09) o Case: A man in his early 60s with recurrent, microsatellite stable, HER2-negative, RAS WT rectal cancer, currently receiving TAS-102/bevacizumab — Swati Vishwanathan, MD (35:16) • HER2-Positive Disease o Case: A woman in her mid 50s with RAS WT, HER2-amplified metastatic colon adenocarcinoma — Gigi Chen, MD (44:38) o Case: A woman in her mid 60s with multiregimen-relapsed RAS WT, HER2-positive metastatic rectal cancer, now receiving trastuzumab/tucatinib — Sunil Gandhi, MD (50:47) • Microsatellite Instability-High Disease; BRAF-Mutant Disease o Case: A woman in her late 70s with HER2-negative, BRAF V600E-mutant, microsatellite stable metastatic colon cancer after mFOLFOX/bevacizumab followed by maintenance 5-FU/bevacizumab — Victoria Giffi, MD (58:14) CME information and select publications

Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer | Faculty Presentation 2: Tolerability and Other Practical Issues with OFS, Including Its Potential Utility in Preserving Fertility — Dr Ann Patridge CME information and select publications

Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer | Faculty Presentation 1: Optimizing the Use of Ovarian Function Suppression (OFS)/Ablation in the Care of Patients with Breast Cancer — Dr Kathy Miller CME information and select publications

Featuring perspectives from Dr Matthew Lunning, including the following topics: · Introduction (00:00) · Case: A woman in her mid 20s with T1cN0M0, ER/PR-positive, HER2-negative breast cancer, Recurrence Score® (RS) of 26 — Dr Partridge (10:03) · Case: A woman in her late 20s with a 2.8-cm ER/PR-positive, HER2-positive Grade III intraductal carcinoma — Dr Miller (26:42) · Case: A woman in her mid 30s with a 3.5-cm ER/PR-negative, HER2-negative breast cancer with a BRCA2 mutation — Dr Partridge (41:01) · Case: A woman in her early 30s with ER/PR-positive, HER2-negative inflammatory breast cancer — Dr Miller (52:28) CME information and select publications